Veracyte Launches Early Access Program for Envisia Genomic Classifier Test to Improve IPF Diagnosis

  • Research and Development

    Veracyte Launches Early Access Program for Envisia Genomic Classifier Test to Improve IPF Diagnosis

    Posted by Pulmonary Fibrosis News Moderator on May 24, 2018 at 9:10 am

    Veracyte, a leading genomic diagnostics company, launched an Early Access Program to make its Envisia Genomic Classifier test available for idiopathic pulmonary fibrosis (IPF) patients, the company announced. Envisia Genomic Classifier was designed to improve the diagnosis of IPF and help ensure an appropriate treatment without requiring surgery.

    Read more about Veracyte and its Envisia Genomic Classifier here: Veracyte Launches Early Access Program for Envisia Genomic Classifier Test to Improve IPF Diagnosis

    Are you familiar with Veracyte or its Envisia Genomic Classifier? Do you know anyone who would benefit from access to this Early Access Program?

    replied 6 years, 6 months ago 1 Member · 0 Replies
  • 0 Replies

Sorry, there were no replies found.

Log in to reply.

Start of Discussion
0 of 0 replies June 2018
Now

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Invite this member to groups
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .